308 related articles for article (PubMed ID: 26951557)
1. Tolerability of toceranib phosphate (Palladia) when used in conjunction with other therapies in 35 cats with feline oral squamous cell carcinoma: 2009-2013.
Olmsted GA; Farrelly J; Post GS; Smith J
J Feline Med Surg; 2017 Jun; 19(6):568-575. PubMed ID: 26951557
[TBL] [Abstract][Full Text] [Related]
2. Retrospective evaluation of toceranib phosphate (Palladia) in cats with oral squamous cell carcinoma.
Wiles V; Hohenhaus A; Lamb K; Zaidi B; Camps-Palau M; Leibman N
J Feline Med Surg; 2017 Feb; 19(2):185-193. PubMed ID: 26755491
[TBL] [Abstract][Full Text] [Related]
3. Toxicity and response in cats with neoplasia treated with toceranib phosphate.
Harper A; Blackwood L
J Feline Med Surg; 2017 Jun; 19(6):619-623. PubMed ID: 27090289
[TBL] [Abstract][Full Text] [Related]
4. Retrospective evaluation of toceranib phosphate (Palladia®) toxicity in cats.
Merrick CH; Pierro J; Schleis SE; Sones EA; Wright ZM; Regan RC; Siedlecki CT; Bergman PJ
Vet Comp Oncol; 2017 Sep; 15(3):710-717. PubMed ID: 27041701
[TBL] [Abstract][Full Text] [Related]
5. Retrospective evaluation of toceranib phosphate (Palladia) use in cats with mast cell neoplasia.
Berger EP; Johannes CM; Post GS; Rothchild G; Shiu KB; Wetzel S; Fox LE
J Feline Med Surg; 2018 Feb; 20(2):95-102. PubMed ID: 29172873
[TBL] [Abstract][Full Text] [Related]
6. Retrospective evaluation of toceranib phosphate (Palladia) use in the treatment of feline pancreatic carcinoma.
Rosario CO; Musser ML; Yuan L; Mochel JP; Talbott J; Johannes CM; Berger EP
Can Vet J; 2023 Dec; 64(12):1143-1148. PubMed ID: 38046430
[TBL] [Abstract][Full Text] [Related]
7. Retrospective evaluation of canine heart base tumours treated with toceranib phosphate (Palladia): 2011-2018.
Lew FH; McQuown B; Borrego J; Cunningham S; Burgess KE
Vet Comp Oncol; 2019 Dec; 17(4):465-471. PubMed ID: 31069932
[TBL] [Abstract][Full Text] [Related]
8. Palliative radiation therapy outcomes for cats with oral squamous cell carcinoma (1999-2005).
Sabhlok A; Ayl R
Vet Radiol Ultrasound; 2014; 55(5):565-70. PubMed ID: 24766180
[TBL] [Abstract][Full Text] [Related]
9. Treatment of oral squamous cell carcinoma with accelerated radiation therapy and concomitant carboplatin in cats.
Fidel J; Lyons J; Tripp C; Houston R; Wheeler B; Ruiz A
J Vet Intern Med; 2011; 25(3):504-10. PubMed ID: 21539605
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and toxicity of an accelerated hypofractionated radiation therapy protocol in cats with oral squamous cell carcinoma.
Poirier VJ; Kaser-Hotz B; Vail DM; Straw RC
Vet Radiol Ultrasound; 2013; 54(1):81-8. PubMed ID: 23078236
[TBL] [Abstract][Full Text] [Related]
11. The tyrosine kinase inhibitor toceranib in feline injection site sarcoma: efficacy and side effects.
Holtermann N; Kiupel M; Hirschberger J
Vet Comp Oncol; 2017 Jun; 15(2):632-640. PubMed ID: 26762970
[TBL] [Abstract][Full Text] [Related]
12. Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study.
Pellin MA; Wouda RM; Robinson K; Tsimbas K; Kurzman ID; Biller BJ; Vail DM
Vet Comp Oncol; 2017 Sep; 15(3):919-931. PubMed ID: 27146577
[TBL] [Abstract][Full Text] [Related]
13. Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study.
Wouda RM; Hocker SE; Higginbotham ML
Vet Comp Oncol; 2018 Mar; 16(1):E52-E60. PubMed ID: 28799187
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine as a radiosensitizer for nonresectable feline oral squamous cell carcinoma.
Jones PD; de Lorimier LP; Kitchell BE; Losonsky JM
J Am Anim Hosp Assoc; 2003; 39(5):463-7. PubMed ID: 14518654
[TBL] [Abstract][Full Text] [Related]
15. Long-term clinical control of feline pancreatic carcinoma with toceranib phosphate.
Dedeaux AM; Langohr IM; Boudreaux BB
Can Vet J; 2018 Jul; 59(7):751-754. PubMed ID: 30026621
[TBL] [Abstract][Full Text] [Related]
16. Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study.
Chon E; McCartan L; Kubicek LN; Vail DM
Vet Comp Oncol; 2012 Sep; 10(3):184-93. PubMed ID: 22235941
[TBL] [Abstract][Full Text] [Related]
17. Retrospective evaluation of toceranib phosphate (Palladia) in the treatment of canine carcinomatosis and mesothelioma.
Hicks KA; Leeper HJ; Curran KM
Vet Comp Oncol; 2024 Jun; 22(2):245-254. PubMed ID: 38622074
[TBL] [Abstract][Full Text] [Related]
18. Toxicity and outcome in cats with oral squamous cell carcinoma after accelerated hypofractionated radiotherapy and concurrent systemic treatment.
Marconato L; Weyland M; Tresch N; Rossi F; Leone V; Rohrer Bley C
Vet Comp Oncol; 2020 Sep; 18(3):362-369. PubMed ID: 31756259
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.
Bernabe LF; Portela R; Nguyen S; Kisseberth WC; Pennell M; Yancey MF; London CA
BMC Vet Res; 2013 Sep; 9():190. PubMed ID: 24079884
[TBL] [Abstract][Full Text] [Related]
20. Use of cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II), a liposomal cisplatin analogue, in cats with oral squamous cell carcinoma.
Fox LE; Rosenthal RC; King RR; Levine PB; Vail DM; Helfand SC; MacEwen EG; Perez-Soler R; Calderwood-Mays M; Kurzman ID
Am J Vet Res; 2000 Jul; 61(7):791-5. PubMed ID: 10895902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]